An unusual Staphylococcus saccharolyticus spondylodiscitis post kyphoplasty: a case report.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
23 Jul 2020
Historique:
received: 17 03 2020
accepted: 16 07 2020
entrez: 25 7 2020
pubmed: 25 7 2020
medline: 22 8 2020
Statut: epublish

Résumé

Staphylococcus saccharolyticus is a rarely encountered coagulase-negative, which grows slowly and its strictly anaerobic staphylococcus from the skin. It is usually considered a contaminant, but some rare reports have described deep-seated infections. Virulence factors remain poorly known, although, genomic analysis highlights pathogenic potential. We report a case of Staphylococcus saccharolyticus spondylodiscitis that followed kyphoplasty, a procedure associated with a low rate but possible severe infectious complication (0.46%), and have reviewed the literature. This case specifically stresses the risk of healthcare-associated S. saccharolyticus infection in high-risk patients (those with a history of alcoholism and heavy smoking). S. saccharolyticus infection is difficult to diagnose due to microbiological characteristics of this bacterium; it requires timely treatment, and improved infection control procedure should be encouraged for high-risk patients.

Sections du résumé

BACKGROUND BACKGROUND
Staphylococcus saccharolyticus is a rarely encountered coagulase-negative, which grows slowly and its strictly anaerobic staphylococcus from the skin. It is usually considered a contaminant, but some rare reports have described deep-seated infections. Virulence factors remain poorly known, although, genomic analysis highlights pathogenic potential.
CASE PRESENTATION METHODS
We report a case of Staphylococcus saccharolyticus spondylodiscitis that followed kyphoplasty, a procedure associated with a low rate but possible severe infectious complication (0.46%), and have reviewed the literature. This case specifically stresses the risk of healthcare-associated S. saccharolyticus infection in high-risk patients (those with a history of alcoholism and heavy smoking).
CONCLUSION CONCLUSIONS
S. saccharolyticus infection is difficult to diagnose due to microbiological characteristics of this bacterium; it requires timely treatment, and improved infection control procedure should be encouraged for high-risk patients.

Identifiants

pubmed: 32703263
doi: 10.1186/s12879-020-05263-5
pii: 10.1186/s12879-020-05263-5
pmc: PMC7379344
doi:

Substances chimiques

Anti-Bacterial Agents 0
Coagulase 0
Amoxicillin 804826J2HU

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

539

Références

BMC Infect Dis. 2018 Nov 12;18(1):555
pubmed: 30419832
J Med Case Rep. 2011 Mar 13;5:101
pubmed: 21396128
J Clin Microbiol. 1978 Mar;7(3):261-4
pubmed: 649761
Joint Bone Spine. 2005 Jan;72(1):91-3
pubmed: 15681259
J Clin Microbiol. 1990 Dec;28(12):2818-9
pubmed: 2280017
Eur Rev Med Pharmacol Sci. 2015 Apr;19(7):1161-3
pubmed: 25912574
Int J Infect Dis. 2009 Mar;13(2):e43-6
pubmed: 18815064
Clin Infect Dis. 1996 Apr;22(4):722-3
pubmed: 8729221
Case Rep Infect Dis. 2017;2017:3713212
pubmed: 29109878
J Biomater Appl. 2011 Sep;26(3):277-92
pubmed: 20566659
Orthopedics. 2009 Jan;32(1):60
pubmed: 19226022
Front Microbiol. 2019 Mar 12;10:478
pubmed: 30915059
Spine J. 2013 Dec;13(12):1809-17
pubmed: 23880354
Front Microbiol. 2015 Jan 13;5:787
pubmed: 25628618
J R Soc Interface. 2013 Jan 6;10(78):20120647
pubmed: 23097502

Auteurs

Marie-Charlotte Trojani (MC)

Département de Rhumatologie, Université Cote d'Azur, CHU de Nice, Nice, France. mctroj@hotmail.fr.

Brigitte Lamy (B)

Laboratoire de Bactériologie, Hôpital L'archet 2, CHU de Nice, Nice, France.
INSERM U1065, Centre Méditerranéen de Médecine Moléculaire, Equipe 6, Nice, France.
Faculté de Médecine, Université Côte d'Azur, Nice, France.

Raymond Ruimy (R)

Laboratoire de Bactériologie, Hôpital L'archet 2, CHU de Nice, Nice, France.
INSERM U1065, Centre Méditerranéen de Médecine Moléculaire, Equipe 6, Nice, France.
Faculté de Médecine, Université Côte d'Azur, Nice, France.

Nicolas Amoretti (N)

Département de Radiologie, Université Cote d'Azur, CHU de Nice, Nice, France.

Karine Risso (K)

Service d'infectiologie, Université Nice Côte d'Azur, CHU de Nice, Nice, France.

Christian Roux (C)

Département de Rhumatologie, Université Cote d'Azur, LAHMESS EA6309, CNRS, iBV UMR 7277, CHU de Nice, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH